Компания SignalChem заключила лицензионное соглашение с Monod Bio для внедрения технологий ИИ в разработку биосенсоров

Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc., today announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. Under the terms of the agreement, SignalChem Biotech may incorporate the Monod Bio technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use. The collaboration expands SignalChem’s specialized CRO capabilities and supports Sino Biological’s broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio. By incorporating Monod Bio’s AI-designed protein technologies into SignalChem’s custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently.” Dr. Rob Burgess, Chief Business Officer, Sino Biological Monod Bio’s LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins engineered for high-performance recognition of various targets. Together, the technologies provide versatile tools for developing customized assays and discovery workflows. “SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base” said Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio.“This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services.”